RU2018129747A - Внутрижелудочковая доставка ферментов при лизосомных болезнях накопления - Google Patents
Внутрижелудочковая доставка ферментов при лизосомных болезнях накопления Download PDFInfo
- Publication number
- RU2018129747A RU2018129747A RU2018129747A RU2018129747A RU2018129747A RU 2018129747 A RU2018129747 A RU 2018129747A RU 2018129747 A RU2018129747 A RU 2018129747A RU 2018129747 A RU2018129747 A RU 2018129747A RU 2018129747 A RU2018129747 A RU 2018129747A
- Authority
- RU
- Russia
- Prior art keywords
- enzyme
- lysosomal storage
- hours
- storage disease
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0102—Alpha-glucosidase (3.2.1.20)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01076—L-Iduronidase (3.2.1.76)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
Claims (13)
1. Способ профилактики или лечения лизосомной болезни накопления, которая вызвана дефицитом фермента у пациента, включающий внутрижелудочковое введение фермента в головной мозг пациента, при этом введение одной дозы фермента занимает более трех часов.
2. Способ по п.1, где введение одной дозы фермента занимает более четырех часов, более пяти часов, более шести часов, более семи часов или более восьми часов.
3. Способ по п.1, где указанная профилактика или лечение включает введение фермента в боковые желудочки и/или в четвертый желудочек головного мозга.
4. Способ по п.1, где введенного пациенту количества фермента достаточно для снижения уровня фермента в печени, легких, селезенки или почках пациента.
5. Способ по п.1, где профилактика или лечение включает мониторинг уровней сфингомиелина у пациента и введение дополнительного фермента в ответ на зарегистрированные уровни фермента.
6. Способ по п.1, где фермент вводят с помощью постоянного катетера.
7. Способ по п.1, где введение включает множественные инфузии.
8. Способ по любому из пп.1-7, где лизосомная болезнь накопления является синдромом мукополисахаридоза типа I, и фермент является альфа-L-идуронидазой.
9. Способ по любому из пп.1-7, где лизосомная болезнь накопления является синдромом мукополисахаридоза типа II, и фермент является идуронат-2-сульфатазой.
10. Способ по любому из пп.1-7, где лизосомная болезнь накопления является болезнью Гоше, и фермент является глюкоцереброзидазой.
11. Способ по любому из пп.1-7, где лизосомная болезнь накопления является болезнью Помпе, и фермент является альфа-глюкозидазой.
12. Способ по любому из пп.1-7, где лизосомная болезнь накопления является классической поздней инфантильной болезнью Баттена (CLN2), и фермент является трипептидилпептидазой.
13. Способ по любому из пп.1-7, где лизосомная болезнь накопления является одним из заболеваний, указанных в таблице 1, и фермент является соответствующим дефектным ферментом, указанным в таблице 1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76037806P | 2006-01-20 | 2006-01-20 | |
US60/760,378 | 2006-01-20 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2014129319A Division RU2665381C2 (ru) | 2006-01-20 | 2014-07-16 | Внутрижелудочковая доставка ферментов при лизосомных болезнях накопления |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2018129747A true RU2018129747A (ru) | 2020-02-19 |
Family
ID=38288294
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2008134120/15A RU2529830C2 (ru) | 2006-01-20 | 2007-01-22 | Внутрижелудочковая доставка ферментов при лизосомных болезнях накопления |
RU2014129319A RU2665381C2 (ru) | 2006-01-20 | 2014-07-16 | Внутрижелудочковая доставка ферментов при лизосомных болезнях накопления |
RU2018129747A RU2018129747A (ru) | 2006-01-20 | 2018-08-15 | Внутрижелудочковая доставка ферментов при лизосомных болезнях накопления |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2008134120/15A RU2529830C2 (ru) | 2006-01-20 | 2007-01-22 | Внутрижелудочковая доставка ферментов при лизосомных болезнях накопления |
RU2014129319A RU2665381C2 (ru) | 2006-01-20 | 2014-07-16 | Внутрижелудочковая доставка ферментов при лизосомных болезнях накопления |
Country Status (19)
Country | Link |
---|---|
US (4) | US8926967B2 (ru) |
EP (3) | EP2666476B1 (ru) |
JP (1) | JP5681345B2 (ru) |
CN (1) | CN101431960A (ru) |
AR (2) | AR059089A1 (ru) |
BR (1) | BRPI0706699A2 (ru) |
CA (2) | CA2966155A1 (ru) |
DK (2) | DK2666476T3 (ru) |
ES (2) | ES2526710T3 (ru) |
HU (1) | HUE041840T2 (ru) |
IL (2) | IL192740A (ru) |
LT (1) | LT2666476T (ru) |
MX (1) | MX349749B (ru) |
PL (2) | PL2666476T3 (ru) |
PT (2) | PT1984018E (ru) |
RU (3) | RU2529830C2 (ru) |
SI (2) | SI2666476T1 (ru) |
TR (1) | TR201903855T4 (ru) |
WO (1) | WO2007084737A2 (ru) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR059089A1 (es) | 2006-01-20 | 2008-03-12 | Genzyme Corp | Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal |
LT1988823T (lt) | 2006-02-09 | 2018-12-10 | Genzyme Corporation | Lėtas intraventrikuliarinis pateikimas |
CA2684946C (en) | 2007-05-16 | 2015-03-31 | The Brigham And Women's Hospital, Inc. | Treatment of synucleinopathies |
CN105879047A (zh) * | 2008-12-16 | 2016-08-24 | 建新公司 | 寡糖-蛋白缀合物 |
LT3421603T (lt) | 2009-05-02 | 2022-01-10 | Genzyme Corporation | Genų terapija, skirta neurodegeneraciniams sutrikimams |
IL300625A (en) * | 2009-08-28 | 2023-04-01 | Icahn School Med Mount Sinai | Increasing dose replacement enzyme for the treatment of acid sphingomyelinase deficiency |
SI3205351T1 (sl) | 2010-04-23 | 2023-09-29 | Alexion Pharmaceuticals, Inc., | Encim za bolezen lizosomskega shranjevanja |
ES2754234T3 (es) | 2010-06-25 | 2020-04-16 | Shire Human Genetic Therapies | Métodos y composiciones para la administración SNC de iduronato-2-sulfatasa |
DK2588130T3 (en) * | 2010-06-25 | 2016-10-24 | Shire Human Genetic Therapies | Cns delivery of therapeutic agents |
US20110318324A1 (en) * | 2010-06-25 | 2011-12-29 | Shire Human Genetic Therapies, Inc. | Methods and compositions for cns delivery of b-galactocerebrosidase |
RU2012154576A (ru) * | 2010-06-25 | 2014-07-27 | Шир Хьюман Дженетик Терапис, Инк. | Способы и композиции для доставки к цнс гепаран-n-сульфатазы |
LT2585104T (lt) * | 2010-06-25 | 2019-10-25 | Shire Human Genetic Therapies | Būdai ir kompozicijos, skirti arilsulfatazės a pristatymui į cns |
LT3626258T (lt) | 2010-06-25 | 2021-12-10 | Shire Human Genetic Therapies, Inc. | Būdai ir kompozicijos, skirti iduronato-2-sulfatazės įvedimui į cns |
JP2012062312A (ja) * | 2010-08-19 | 2012-03-29 | Yoshikatsu Eto | ハンター症候群の治療剤 |
SG188456A1 (en) * | 2010-09-09 | 2013-04-30 | Synageva Biopharma Corp | Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients |
US9387236B2 (en) * | 2011-06-10 | 2016-07-12 | Prothera Inc. | Pharmaceutical compositions containing protease and methods for the treatment of lysosomal storage diseases |
WO2013096912A2 (en) * | 2011-12-23 | 2013-06-27 | Shire Human Genetic Therapies, Inc. | Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase |
WO2013096899A2 (en) | 2011-12-23 | 2013-06-27 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
EA039246B1 (ru) * | 2012-12-06 | 2021-12-22 | Шир Хьюман Дженетик Терапис, Инк. | Способ лечения когнитивных нарушений, связанных с синдромом хантера |
CN105189542A (zh) | 2013-02-20 | 2015-12-23 | 瓦莱里昂治疗有限责任公司 | 用于治疗庞贝氏症的方法和组合物 |
SG10201709925SA (en) | 2013-06-07 | 2017-12-28 | Genzyme Corp | Marker for acid sphingomyelinase disorders and uses thereof |
JP6616189B2 (ja) | 2013-12-25 | 2019-12-04 | Jcrファーマ株式会社 | 血液脳関門を通過する新規抗トランスフェリン受容体抗体 |
WO2015119989A1 (en) * | 2014-02-04 | 2015-08-13 | New York University | Progranulin (pgrn) and its derivatives for diagnosis and treatment of lysosomal storage diseases |
GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
AU2016283343B2 (en) | 2015-06-24 | 2022-05-19 | Jcr Pharmaceuticals Co., Ltd. | Anti-human transferrin receptor antibody permeating blood-brain barrier |
CA2990565A1 (en) | 2015-06-24 | 2016-12-29 | Jcr Pharmaceuticals Co., Ltd. | Fusion protein containing bdnf and anti-human transferrin receptor antibody |
US11390656B2 (en) * | 2015-08-04 | 2022-07-19 | New York University | Progranulin (PGRN) fragments and derivatives for treatment or alleviation of lysosomal storage diseases |
RU2634113C1 (ru) * | 2016-11-18 | 2017-10-24 | Государственное бюджетное учреждение "Академия наук Республики Саха (Якутия)" (ГБУ АН РС(Я)) | Способ фиксации головного мозга ископаемого позднеплейстоценового млекопитающего |
MX2019007719A (es) | 2016-12-26 | 2019-09-09 | Japan Chem Res | Anticuerpo anti-receptor de transferrina humana novedoso capaz de penetrar la barrera hematoencefalica. |
EP3561058A4 (en) | 2016-12-26 | 2020-07-22 | JCR Pharmaceuticals Co., Ltd. | FUSION PROTEIN INCLUDING BDNF |
JP2021500857A (ja) | 2017-10-02 | 2021-01-14 | デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. | 酵素補充療法用酵素を含む融合タンパク質 |
UY38238A (es) * | 2018-05-25 | 2019-12-31 | Genzyme Corp | Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida |
AU2020215263A1 (en) | 2019-02-01 | 2021-09-09 | Oxyrane Uk Ltd | Glucocerebrosidase polypeptides |
RU2723187C1 (ru) * | 2019-10-04 | 2020-06-09 | федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) | Генетическая кассета, содержащая кодон-оптимизированные нуклеотидные последовательности генов HEXA и HEXВ, и фармацевтическая композиция для лечения болезни Тея-Сакса |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8303626D0 (sv) | 1983-06-23 | 1983-06-23 | Kabigen Ab | A recombinant plasmid a transformant microorganism, a polydoxyrebonucleotide segment, a process for producing a biologically active protein, and the protein thus produced |
US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
US5919676A (en) | 1993-06-24 | 1999-07-06 | Advec, Inc. | Adenoviral vector system comprising Cre-loxP recombination |
AU7676894A (en) | 1993-08-27 | 1995-03-21 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Convection-enhanced drug delivery |
WO1995029993A1 (en) | 1994-04-28 | 1995-11-09 | The University Of Michigan | Gene delivery vector using plasmid dna packaged into an adenovirus and a packaging cell line |
WO1996033280A1 (en) | 1995-04-17 | 1996-10-24 | Board Of Regents, The University Of Texas System | An adenovirus helper-virus system |
DK1445322T4 (da) | 1995-06-15 | 2012-09-03 | Crucell Holland Bv | Pakningssystemer for humant rekombinant adenovirus til anvendelse ved genterapi |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
NZ330553A (en) | 1996-01-05 | 2001-04-27 | Genetic Therapy Inc | Recombinase-mediated generation of adenoviral vectors where all adenoviral genes of all regions E1 to E4 and L1 to L5 of the adenoviral genome are eliminated |
US5735814A (en) * | 1996-04-30 | 1998-04-07 | Medtronic, Inc. | Techniques of treating neurodegenerative disorders by brain infusion |
ES2581828T3 (es) * | 1996-09-13 | 2016-09-07 | Shire Human Genetic Therapies, Inc. | Proceso de purificación de alfa-galactosidasa A |
US7033598B2 (en) | 1996-11-19 | 2006-04-25 | Intrabrain International N.V. | Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal |
US6042579A (en) | 1997-04-30 | 2000-03-28 | Medtronic, Inc. | Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
WO1999057296A1 (en) | 1998-05-01 | 1999-11-11 | Genzyme Corporation | Partially deleted adenoviral vectors |
US6702945B2 (en) | 2000-12-28 | 2004-03-09 | Exxonmobil Research And Engineering Company | Ionic membranes for organic sulfur separation from liquid hydrocarbon solutions |
US6689756B2 (en) | 2001-03-02 | 2004-02-10 | Integra Lifesciences Corporation | Treatment of neurological disease |
US20030163181A1 (en) | 2001-12-07 | 2003-08-28 | Neuron Therapeutics, Inc. | Protection of neurological tissue by direct CNS perfusion cooling |
WO2004047768A2 (en) | 2002-11-26 | 2004-06-10 | Seacoast Neuroscience, Inc. | Buoyant polymer particles delivering therapeutic agents |
JP2006519609A (ja) | 2003-03-12 | 2006-08-31 | サマリタン・ファーマシューティカルズ・インコーポレイテッド | 神経疾患擬態動物モデル |
US20040258666A1 (en) | 2003-05-01 | 2004-12-23 | Passini Marco A. | Gene therapy for neurometabolic disorders |
US20050026823A1 (en) | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
EP1638605B1 (en) | 2003-06-20 | 2014-01-08 | Raptor Pharmaceutical, Inc. | Delivery of therapeutic compounds to the brain and other tissues |
US7442372B2 (en) * | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
WO2005072049A2 (en) | 2004-01-27 | 2005-08-11 | Compugen Usa, Inc. | Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of endometriosis |
US20050208090A1 (en) * | 2004-03-18 | 2005-09-22 | Medtronic, Inc. | Methods and systems for treatment of neurological diseases of the central nervous system |
WO2005095955A1 (en) | 2004-03-31 | 2005-10-13 | Children, Youth And Women's Health Service | Screening for lysosomal storage disease status |
WO2005099748A1 (de) * | 2004-04-13 | 2005-10-27 | Cilian Ag | Rekombinante lysosomale enzyme mit ciliaten-typischem glykosylierungsmuster für die therapie |
WO2006007560A2 (en) * | 2004-07-01 | 2006-01-19 | University Of Pennsylvania | Targeted protein replacement for the treatment of lysosomal storage disorders |
AR059088A1 (es) | 2006-01-20 | 2008-03-12 | Genzyme Corp | Administracion intraventricular de una proteina para esclerosis lateral amiotrofica |
AR059089A1 (es) | 2006-01-20 | 2008-03-12 | Genzyme Corp | Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal |
LT1988823T (lt) | 2006-02-09 | 2018-12-10 | Genzyme Corporation | Lėtas intraventrikuliarinis pateikimas |
WO2008154198A1 (en) | 2007-06-06 | 2008-12-18 | Genzyme Corporation | Gene therapy for lysosomal storage diseases |
-
2007
- 2007-01-19 AR ARP070100239A patent/AR059089A1/es not_active Application Discontinuation
- 2007-01-22 PL PL13173895T patent/PL2666476T3/pl unknown
- 2007-01-22 CA CA2966155A patent/CA2966155A1/en not_active Abandoned
- 2007-01-22 EP EP13173895.7A patent/EP2666476B1/en active Active
- 2007-01-22 BR BRPI0706699-6A patent/BRPI0706699A2/pt not_active Application Discontinuation
- 2007-01-22 EP EP18212320.8A patent/EP3517124A1/en not_active Withdrawn
- 2007-01-22 CA CA2636991A patent/CA2636991C/en not_active Expired - Fee Related
- 2007-01-22 EP EP07716858.1A patent/EP1984018B1/en active Active
- 2007-01-22 DK DK13173895.7T patent/DK2666476T3/en active
- 2007-01-22 TR TR2019/03855T patent/TR201903855T4/tr unknown
- 2007-01-22 ES ES07716858.1T patent/ES2526710T3/es active Active
- 2007-01-22 MX MX2013012372A patent/MX349749B/es unknown
- 2007-01-22 PT PT77168581T patent/PT1984018E/pt unknown
- 2007-01-22 SI SI200732098T patent/SI2666476T1/sl unknown
- 2007-01-22 WO PCT/US2007/001566 patent/WO2007084737A2/en active Application Filing
- 2007-01-22 HU HUE13173895A patent/HUE041840T2/hu unknown
- 2007-01-22 SI SI200731529T patent/SI1984018T1/sl unknown
- 2007-01-22 DK DK07716858.1T patent/DK1984018T3/da active
- 2007-01-22 PL PL07716858T patent/PL1984018T3/pl unknown
- 2007-01-22 PT PT13173895T patent/PT2666476T/pt unknown
- 2007-01-22 LT LTEP13173895.7T patent/LT2666476T/lt unknown
- 2007-01-22 JP JP2008551442A patent/JP5681345B2/ja not_active Expired - Fee Related
- 2007-01-22 ES ES13173895T patent/ES2716206T3/es active Active
- 2007-01-22 CN CNA2007800069255A patent/CN101431960A/zh active Pending
- 2007-01-22 RU RU2008134120/15A patent/RU2529830C2/ru not_active IP Right Cessation
-
2008
- 2008-07-10 IL IL192740A patent/IL192740A/en not_active IP Right Cessation
- 2008-07-18 US US12/175,610 patent/US8926967B2/en active Active
-
2014
- 2014-07-16 RU RU2014129319A patent/RU2665381C2/ru not_active IP Right Cessation
- 2014-12-03 US US14/559,851 patent/US10080783B2/en active Active
-
2017
- 2017-03-05 IL IL250937A patent/IL250937A0/en unknown
- 2017-07-27 AR ARP170102114A patent/AR109170A2/es unknown
-
2018
- 2018-08-15 RU RU2018129747A patent/RU2018129747A/ru not_active Application Discontinuation
- 2018-08-23 US US16/111,009 patent/US20190083582A1/en not_active Abandoned
-
2020
- 2020-12-29 US US17/137,060 patent/US20210228692A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2018129747A (ru) | Внутрижелудочковая доставка ферментов при лизосомных болезнях накопления | |
US20220370348A1 (en) | Slow intraventricular delivery | |
Grabowski et al. | Gaucher disease | |
JP4633939B2 (ja) | 治療におけるグルコシルセラミド合成阻害剤と糖脂質分解酵素の組み合わせ | |
JP2013544263A5 (ru) | ||
FI3578195T3 (fi) | Hsp70:n käyttö entsyymitoiminnan säätelijänä | |
US11571407B2 (en) | Bicalutamide analogs or (S)-bicalutamide as exocytosis activating compounds for use in the treatment of a lysosomal storage disorder or glycogenosis | |
CN1227029C (zh) | 转化酶抑制剂和利尿剂的组合在治疗微循环紊乱中的应用 | |
Lou et al. | Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism | |
Olson et al. | The parasympatholytic effects of atropine sulfate and glycopyrrolate in rats and rabbits. | |
Hopwood et al. | Galsulfase. | |
CN108403881A (zh) | 一种治疗老年痴呆的药物组合物及其制备方法与用途 | |
Riddell et al. | Severe sepsis: patient management focusing on administration of drotrecogin alpha (activated) infusion | |
Barranger et al. | Gaucher Disease: Review and Perspectives on Treatment | |
CN115137728A (zh) | 醇化合物1在制备治疗肺动脉高压的药物中的应用 | |
RU2021134682A (ru) | Доставка терапевтических агентов в цнс | |
Sohn et al. | Substrate reduction therapy as a new treatment option for patients with Gaucher disease type 1: A review of literatures |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20210816 |